Efficacy of SU 011248 in Head And Neck Carcinoma

Summary

Preclinical studies as well as phase I and II trials have demonstrated that SU11248 has antitumor activity in renal cell carcinoma, breast cancer, neuroendocrine tumor and GIST. So at the light of these pre-clinical and clinical data, it seems interesting and promising to test SU011248 in these poor prognosis patients.

Timeline

Start

2007-02

Primary completion

2011-12

Completion

2011-12

Outcome

Outcome not reported

Stopped: “Too frequent grade 3-4 toxicities”

Drugs

Indications